The Impact of Independent Publicly Funded Biomedical Research

My research articles are still the most downloaded and cited in the journals in which they were published.

I’m not the competitive type, so I’m sending this message out in gratitude.

I found out yesterday that two years later, my article “Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation”, published with co-authors, is still the most actively downloaded article in the last 90 days from the Journal of Trace Elements in Medicine and Biology, followed by the study by Mold et al. on “Aluminium in brain tissue in autism” from 2018, and then the third-most is my paper with Dr. Ricketson in which we established the world’s first pediatric dose limit for aluminum from vaccines: “Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum”, also from 2018. Coming in fourth is the paper by Kern et al. from 2016 “The relationship between mercury and autism: A comprehensive review and discussion”. That’s some staying power!

And now I’ve been alerted that my study introducing pathogenic priming is the most cited paper in the Journal of Translational Autoimmunity since 2018. The results of that study, “Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity”, were validated by a team from Harvard University, setting the stage for an understanding of the important role of autoimmunity in COVID-19 and in vaccine-induced autoimmunity (including that against immune system proteins). (See 45 studies that cite this article here).

I am pleased to be able to say “Thank You” to the monthly supporters of IPAK for helping us conduct impactful research - and being able to afford the open access charges required to make these studies widely available.

We have additional studies underway, including three that I will highlight today.

• A comparison of aluminum toxicity in the pediatric schedule across various countries. This will allow us to compare rates of various conditions such as autoimmune conditions across countries and ask the question “which country has the highest pediatric aluminum toxicity”, and “why do some countries get to avoid aluminum”.

• A study of pathogenic priming in Hepatitis B virus and Hepatitis B vaccines

• The role of pre-existing autoimmunity in severe COVID-19 (hint: it’s pathogenic priming all over again).

If you’re not yet an IPAK Science Hero, you can drive these studies forward and join the others who have helped IPAK conduct such impactful research.

NB: Before my study with Paul Thomas was wrongfully retracted in an MDPI journal, it had over 250,000 reads. I an certain that study would place it among the most read articles in that journal, as well. A re-assessment of “Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnosis” is also a project at IPAK, but I won’t say more about this due to the attack by the medical board on Dr. Thomas’ license, so please don’t ask because I can’t answer.